Become A Featured Company

Top 5 Health Benefits of Medical Marijuana

Ryan Allway

December 3rd, 2015

Policy, Top Story

CFN-03072014-1Medical marijuana has been legalized in 23 U.S. states and Washington DC, while non-psychoactive derivatives of the drug have been approved in even more states. While politicians have long debated the merits of medical marijuana, researchers have become increasingly convinced that the drug may provide many different health benefits. These studies have led an increasing number of doctors to prescribe medical marijuana for patients in legal states.

There are more than 85 different cannabinoids present in the marijuana plant, but the most well-studied are cannabidiol (CBD) – which impacts the brain without a “high” – and tetrahydrocannabinol (THC) – which may help relieve pain and other symptoms. In addition, pharmaceutical companies like GW Pharmaceuticals plc have developed synthetic cannabinoids that incorporate a number of different chemical classes.

  1. It helps control seizures.

GW Pharmaceuticals gave epileptic patients a CBD-based cannabinoid derivative called Epidiolex and found that seizures decreased by an average of 54% in 137 of the 213 individuals, according to the Epilepsy Foundation. In cases of Dravet Syndrome, patients reported a 63% decrease in seizures over three months with the improvement lasting through 24 weeks. Only 14 patients withdrew from the study because the drug wasn’t effective for them.

The findings were presented at the American Academy of Neurology on April 22, 2015.

  1. It alleviates pain and nausea.

 Medical marijuana appears to be effective in treating pain and nausea stemming from diabetes, cancer, multiple sclerosis, and HIV. In fact, a randomized, placebo-controlled clinical trial demonstrated that smoking medical marijuana reduces neuropathy in patients with HIV by 30% compared to placebo, while a separate study showed improvements in pain, sleep quality, and anxiety in patients with refractory pain where conventional therapies failed.

These studies were published in the Journal of Neurology and CMAJ.

  1. It may help veterans with PTSD.

Controlled clinical data assessing cannabis’ impact on PTSD isn’t available yet, but observational data has showed strong promise for the drug. A 2014 review of patients found a greater than 75% reduction in Clinical Administered Posttraumatic Stress (CAPS) Scale symptoms scores following a cannabis-based therapy. A separate study found that oral THC led to improvements in symptom severity, sleep equality, nightmare frequency, and other symptoms in 10 subjects.

These studies were published in the Journal of Psychoactive Drugs and Clinical Drug Investigation.

  1. It may kill cancer cells.

St. George’s University of London researchers found reductions in high-grade glioma tumors – a highly aggressive and lethal form of brain cancer – in mice that were exposed to radiation in conjunction with THCs and CBDs. According to the published study, the cannabinoids may have made the tumors more receptive to radiation treatment. These findings have been mirrored in a number of other studies across various types of cancer.

The study was published in the American Association for Cancer Research.

  1. It may treat heart disease.

The cannabinoid system plays a key role in regulating blood pressure and influencing various cardiovascular systems. In animal studies, the administration of cannabinoids was associated with vasodialation, hypotension, and inhibition of atherosclerosis progression, which suggests that the drug could be helpful in treating heart disease. However, the research remains in its early stages and there’s much work to be done to prove anything.

These studies were published in Nature and the Current Opinion in Lipidology among other journals.

Medical Marijuana’s Other Health Benefits

Medical marijuana’s health benefits may extend well beyond these five indications and into areas as diverse as Alzheimer’s diseases, sleep apnea, and osteoporosis. As federal and state governments continue to realize the potential benefits of cannabinoids like THC and CBD, patients may benefit from a greater amount of high quality research that could lead to new treatments for some of the most serious unmet medical needs in society.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading